Revolution Medicines is a drug development company finding new treatments for cancer patients. One of the many pathways that become aberrantly activated in human cancers is the RAS and related pathways. Revolution Medicines is using expertise from cellular and structural biology combined with drug discovery and synthetic chemistry to create a pipeline of drugs targeting the RAS pathway. The drugs fall into two categories: RAS(ON) inhibitors that bind RAS directly and RAS Companion Inhibitors that target RAS signaling partners. Revolution’s most advanced candidate is a RAS Companion Inhibitor, RMC-4630, which is being evaluated in Phase 2 clinical trials for a range of tumor types.